Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients
Abstract Background Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic colorectal cancer patients, but its mechanisms are unknown. We recently found, using data of the randomized phase 3 CAIRO3 study, that SMI...
Main Authors: | Sophie Kurk, Petra Peeters, Rebecca Stellato, B. Dorresteijn, Pim deJong, Marion Jourdan, Geert‐Jan Creemers, Frans Erdkamp, Felix deJongh, Peter Kint, Lieke Simkens, Bea Tanis, Manuel Tjin‐A‐Ton, Ankie Van Der Velden, Cornelis Punt, Miriam Koopman, Anne May |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-08-01
|
Series: | Journal of Cachexia, Sarcopenia and Muscle |
Subjects: | |
Online Access: | https://doi.org/10.1002/jcsm.12436 |
Similar Items
-
Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial
by: Sophie A. Kurk, et al.
Published: (2020-02-01) -
Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients
by: Sophie A. Kurk, et al.
Published: (2018-10-01) -
The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer
by: Jeroen W.G. Derksen, et al.
Published: (2020-08-01) -
Causal processes in the Problem Space Computational Model : integrating multiple representations of causal processes in abductive problem solving /
by: DeJongh, Matthew
Published: (1991) -
Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome
by: DeJongh, B.M
Published: (2021)